Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Long Noncoding RNA PVT1 and MYC Are Co-Regulated By Bromodomain Protein BRD4 in Multiple Myeloma and Associated with Disease Progression

Kazuki Homma, Tsukasa Oda, PhD, Yuki Murakami, Graduate Student, Saki Watanabe, Graduate Student, Rei Ishihara, Graduate Student, Yuko Kuroda, Master, Kei Kimura Masuda, Master, Yuta Masuda, Master, Tetsuhiro Kasamatsu, PhD, Gotoh Nanami, Master, Kenichi Tahara, MD, Nobuhiko Kobayashi, MD, Hiroaki Shimizu, MD PhD, Takuma Ishizaki, MD PhD, Akihiko Yokohama, MD PhD, Norifumi Tsukamoto, MDPhDChief Division, Takayuki Saitoh, MD PhDProf, Hirokazu Murakami, MDPhDProf, Hiroshi Handa, MD PhDChief Division

Blood (2017) 130 (Supplement 1): 4397.

https://doi.org/10.1182/blood.V130.Suppl_1.4397.4397

Published: 2017

Journal Articles

The Role and Therapeutic Target of Base Excision Repair Genes in Multiple Myeloma (MM)

Rumi Ino, Takayuki Saitoh, MD PhDProf, Yuya Kitamura, Kazuki Homma, Noriyuki Takahashi, Gotoh Nanami, Master, Tetsuhiro Kasamatsu, PhD, Hiroaki Shimizu, MD PhD, Makiko Takizawa, PhDMD, Morio Matsumoto, MD, Morio Sawamura, MD PhD, Akihiko Yokohama, MD PhD, Norifumi Tsukamoto, MDPhDChief Division, Hiroshi Handa, MD PhDChief Division, Hirokazu Murakami, MDPhDProf

Blood (2017) 130 (Supplement 1): 4403.

https://doi.org/10.1182/blood.V130.Suppl_1.4403.4403

Published: 2017

Journal Articles

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL)

Hiroaki Shimizu, MD PhD, Satoru Takada, MD, Nahoko Hatsumi, MD, Akihiko Yokohama, MD PhD, Takayuki Saitoh, MD PhDProf, Toru Sakura, PhD MD, Hiroshi Handa, MD PhDChief Division

Blood (2017) 130 (Supplement 1): 2716.

https://doi.org/10.1182/blood.V130.Suppl_1.2716.2716

Published: 2017

Journal Articles

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

Blood (2017) 130 (Supplement 1): 3121.

https://doi.org/10.1182/blood.V130.Suppl_1.3121.3121

Published: 2017

Journal Articles

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Mariko Ishibashi, PhD, Hideto Tamura, MD PhD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Asaka Onodera, MDPhD, Keiichi Moriya, MD PhD, Makoto Sasaki, MD PhD, Hiroshi Handa, MD PhDChief Division, Yoichi Imai, MDPhD, Norina Tanaka, MD, Junji Tanaka, MD PhD, Sakae Tanosaki, MDPhD, Shigeki Ito, MD PhD, Norio Komatsu, MD PhD, Koiti Inokuchi, MD PhD

Blood (2017) 130 (Supplement 1): 3055.

https://doi.org/10.1182/blood.V130.Suppl_1.3055.3055

Published: 2017

Journal Articles

Cytogenetic Alterations Are Differently Associated with Disease Progression Depending on t(14;18) in Follicular Lymphoma

Akihiko Yokohama, MD PhD, Takeki Mitsui, MD PhD, Hiromi Koiso, MD PhD, Akio Saito, MD PhD, Kohtaro Toyama, MD PhD, Hiroaki Shimizu, MD PhD, Takuma Ishizaki, MD PhD, Yoko Hashimoto, MD PhD, Makiko Takizawa, PhDMD, Hiroyuki Irisawa, MD, Kayoko Murayama, MD PhD, Morio Matsumoto, MD, Takayuki Saito, MD PhDProf, Hiroshi Handa, MD PhDChief Division, Hirokazu Murakami, MDPhDProf, Norifumi Tsukamoto, MDPhDChief Division

Blood (2017) 130 (Supplement 1): 5136.

https://doi.org/10.1182/blood.V130.Suppl_1.5136.5136

Published: 2017

Journal Articles

Polymorphisms of Monocyte-Activating Cytokine/Chemokine Genes Affect the Susceptibility to, and Severity of Chronic ITP

Yuya Kitamura, Takayuki Saitoh, MD PhDProf, Rumi Ino, Kazuki Homma, Noriyuki Takahashi, Gotoh Nanami, Master, Tetsuhiro Kasamatsu, PhD, Takuma Ishizaki, MD PhD, Hiroaki Shimizu, MD PhD, Makiko Takizawa, PhDMD, Akihiko Yokohama, MD PhD, Norifumi Tsukamoto, MDPhDChief Division, Hiroshi Handa, MD PhDChief Division, Hirokazu Murakami, MDPhDProf

Blood (2017) 130 (Supplement 1): 3638.

https://doi.org/10.1182/blood.V130.Suppl_1.3638.3638

Published: 2017

Journal Articles

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Naoki Takezako, MD PhD, Kensuke Ohta, MD PhD, Hiroshi Handa, MD PhDChief Division, Mitsuo Hori, MD PhD, Gen Kinoshita, Suresh Shelat, Masafumi Miyoshi, Kohmei Kubo

Blood (2017) 130 (Supplement 1): 434.

https://doi.org/10.1182/blood.V130.Suppl_1.434.434

Published: 2017

NARROW

Long Noncoding RNA PVT1 and MYC Are Co-Regulated By Bromodomain Protein BRD4 in Multiple Myeloma and Associated with Disease Progression

The Role and Therapeutic Target of Base Excision Repair Genes in Multiple Myeloma (MM)

Clinical Significance of Additional Cytogenetic Abnormalities (ACA) Acquired at the First Relapse in Adult Patients with Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL)

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Cytogenetic Alterations Are Differently Associated with Disease Progression Depending on t(14;18) in Follicular Lymphoma

Polymorphisms of Monocyte-Activating Cytokine/Chemokine Genes Affect the Susceptibility to, and Severity of Chronic ITP

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only